RedHill Biopharma Files Pro Forma Financials After Talicia Joint Venture Deal With Cumberland

Claim 70% Off TipRanks This Holiday SeasonUnlock hedge fund-level data and powerful investing tools for smarter, sharper decisions Stay ahead of the market with the latest news and analysis and maximize your portfolio's potentialThe latest announcement is out from RedHill Biopharma ( (RDHL) ). On October 17, 2025, RedHill Biopharma completed a strategic transaction with Cumberland Pharmaceuticals involving Talicia®, its proprietary drug, by selling a 30% equity stake in newly formed Talicia Holdings Inc. (THI), which holds global rights to Talicia and manages its worldwide commercialization. Cumberland agreed to invest $4 million in two tranches in exchange for joint control of THI, leaving RedHill with a 70% stake but shared decision-making authority, leading RedHill to deconsolidate THI and treat its retained interest as an equity-method joint venture under IFRS; the company has now filed unaudited pro forma condensed consolidated financial information to illustrate how this loss of control, classification of Talicia operations as discontinued, and shift to joint venture accounting would have affected its historical results, signaling a structurally different financial profile for RedHill’s future reporting and Talicia-related earnings and risks. The most recent analyst rating on (RDHL) stock is a Sell with a $1.00 price target. To see the full list of analyst forecasts on RedHill Biopharma stock, see the RDHL Stock Forecast page. Spark’s Take on RDHL Stock According to Spark, TipRanks’ AI Analyst, RDHL is a Underperform. RedHill Biopharma’s overall stock score is primarily influenced by its challenging financial performance, characterized by significant losses and high leverage. The technical analysis suggests a bearish trend, further impacting the score. The absence of valuation metrics and earnings call data limits a comprehensive assessment, resulting in a low overall score. To see Spark’s full report on RDHL stock, click here. More about RedHill Biopharma RedHill Biopharma Ltd. is an Israel-based specialty biopharmaceutical company focused on the development and commercialization of proprietary drugs, including its key asset Talicia®, for global markets. The company operates internationally, with an emphasis on gastrointestinal and related therapeutic areas, and is listed in the United States as a foreign private issuer. Average Trading Volume: 961,652 Technical Sentiment Signal: Sell Current Market Cap: $4.95M Learn more about RDHL stock on TipRanks’ Stock Analysis page.